Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...

A daily pill, Kisqali is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor that prevents cancer cells from dividing and growing. This kind of drug is taken with an aromatase inhibitor ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug be used in combination ... the late-stage NATALEE trial. Adjuvant Kisqali plus endocrine therapy reduced the ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

Kisqali was approved as a treatment for early breast cancer by the U.S. Food and Drug Administration (FDA) in September 20245. Regulatory reviews for Kisqali as an EBC treatment are ongoing ...

University of Iowa researchers have landed a $10-million federal grant to develop a new treatment for ovarian cancer. Jill ...

Novartis' strong breast cancer portfolio has the top drug Kisqali, which has put up a spectacular performance. The Zacks Consensus Estimate for Sanofi’s earnings has risen from $4.21 to $4.25 ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...